PE20211497A1 - Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso - Google Patents

Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso

Info

Publication number
PE20211497A1
PE20211497A1 PE2020001901A PE2020001901A PE20211497A1 PE 20211497 A1 PE20211497 A1 PE 20211497A1 PE 2020001901 A PE2020001901 A PE 2020001901A PE 2020001901 A PE2020001901 A PE 2020001901A PE 20211497 A1 PE20211497 A1 PE 20211497A1
Authority
PE
Peru
Prior art keywords
drug
sez6
sez6 antibody
conjugate
methods
Prior art date
Application number
PE2020001901A
Other languages
English (en)
Inventor
David Liu
Julia Gavrilyuk
Alexander Schammel
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of PE20211497A1 publication Critical patent/PE20211497A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

La presente invencion se refiere a un anticuerpo anti-SEZ6 humana y un conjugado farmaco - anticuerpo anti-SEZ6 descrito en la estructura ADC1, donde el anticuerpo anti-SEZ6 comprende una secuencia de cadena pesada de SEQ ID NO:3 y una secuencia de cadena ligera de SEQ ID NO: 4; el farmaco comprende calicheamicina, especificamente N-Ac calicheamicina; y n es 2. Adicionalmente se refiere a un acido nucleico, un vector una celula huesped que comprende el anticuerpo anti-SEZ6, asi tambien, una composicion farmaceutica y un metodo de preparacion que comprende el conjugado ADC. Dicho conjugado es util en el tratamiento del cancer tal por ejemplo en el cancer de pulmon de celulas pequenas.
PE2020001901A 2018-05-30 2019-05-30 Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso PE20211497A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862678061P 2018-05-30 2018-05-30
PCT/US2019/034701 WO2019232241A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use

Publications (1)

Publication Number Publication Date
PE20211497A1 true PE20211497A1 (es) 2021-08-11

Family

ID=66998493

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001901A PE20211497A1 (es) 2018-05-30 2019-05-30 Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso

Country Status (31)

Country Link
US (3) US20210196834A1 (es)
EP (2) EP3710485B8 (es)
JP (1) JP6936399B2 (es)
KR (1) KR20210018316A (es)
CN (1) CN112135843A (es)
AU (1) AU2019278870A1 (es)
BR (1) BR112020024223A2 (es)
CA (1) CA3097199A1 (es)
CL (1) CL2020003044A1 (es)
CO (1) CO2020016151A2 (es)
CR (1) CR20200623A (es)
CY (1) CY1124183T1 (es)
DK (1) DK3710485T3 (es)
EC (1) ECSP20082970A (es)
ES (1) ES2867148T3 (es)
HR (1) HRP20210631T1 (es)
HU (1) HUE053616T2 (es)
IL (1) IL278225A (es)
LT (1) LT3710485T (es)
MA (1) MA51453A (es)
MX (1) MX2020012788A (es)
NZ (1) NZ768778A (es)
PE (1) PE20211497A1 (es)
PH (1) PH12020551968A1 (es)
PL (1) PL3710485T3 (es)
PT (1) PT3710485T (es)
RS (1) RS61770B1 (es)
RU (1) RU2770474C1 (es)
SG (1) SG11202011576VA (es)
SI (1) SI3710485T1 (es)
WO (1) WO2019232241A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152951A (ko) 2021-05-10 2022-11-17 강원대학교산학협력단 항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
EP4327832A1 (en) * 2022-08-26 2024-02-28 AbbVie Inc. Anti-sez6 antibody drug conjugates

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
SI1507556T1 (sl) * 2002-05-02 2016-10-28 Wyeth Holdings Llc Konjugati kaliheamicinski derivat-nosilec
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
CN103476429B (zh) 2010-09-03 2016-08-24 施特姆森特克斯股份有限公司 新型调节剂及使用方法
SG11201405130UA (en) * 2012-02-24 2014-11-27 Stemcentrx Inc Anti sez6 antibodies and methods of use
WO2015003154A1 (en) 2013-07-03 2015-01-08 Histosonics, Inc. Articulating arm limiter for cavitational ultrasound therapy system
AU2014312215B2 (en) * 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
WO2015031541A1 (en) * 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
EA201792312A1 (ru) * 2015-04-21 2018-06-29 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Конструкции на основе калихеамицина и способы их применения
CA3009484A1 (en) * 2015-12-22 2017-06-29 Abbvie Stemcentrx Llc Novel anti-mmp16 antibodies and methods of use
BR112018075653A2 (pt) * 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco

Also Published As

Publication number Publication date
MX2020012788A (es) 2021-02-15
ES2867148T3 (es) 2021-10-20
ECSP20082970A (es) 2021-01-29
PH12020551968A1 (en) 2021-09-13
CA3097199A1 (en) 2019-12-05
US11077203B2 (en) 2021-08-03
PL3710485T3 (pl) 2021-09-13
RU2770474C1 (ru) 2022-04-18
CR20200623A (es) 2021-07-01
IL278225A (en) 2020-11-30
LT3710485T (lt) 2021-05-10
US20210338831A1 (en) 2021-11-04
DK3710485T3 (da) 2021-05-10
PT3710485T (pt) 2021-05-04
SI3710485T1 (sl) 2021-08-31
JP6936399B2 (ja) 2021-09-15
EP3710485B8 (en) 2021-06-23
JP2021508694A (ja) 2021-03-11
WO2019232241A1 (en) 2019-12-05
CL2020003044A1 (es) 2021-04-16
EP3710485B1 (en) 2021-03-31
RS61770B1 (sr) 2021-05-31
NZ768778A (en) 2022-07-01
MA51453A (fr) 2020-09-23
BR112020024223A2 (pt) 2021-03-16
HRP20210631T1 (hr) 2021-05-28
CN112135843A (zh) 2020-12-25
SG11202011576VA (en) 2020-12-30
US20210196834A1 (en) 2021-07-01
CY1124183T1 (el) 2022-05-27
CO2020016151A2 (es) 2021-05-31
US20200316215A1 (en) 2020-10-08
KR20210018316A (ko) 2021-02-17
HUE053616T2 (hu) 2021-07-28
EP3710485A1 (en) 2020-09-23
AU2019278870A1 (en) 2020-10-29
EP3858863A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
CL2018003807A1 (es) Anticuerpo humanizado aislado que une al cd134 humano; molécula de ácido nucleico aislada; vector que comprende a la misma célula anfitriona que comprende al mismo; uso del anticuerpo para potenciar una respuesta inmune; uso del anticuerpo para el tratamiento del cáncer, una composición farmacéutica que comprende el anticuerpo. (divisional solicitud 201502793)
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR107444A1 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
AR091702A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
ES2721753T3 (es) Anticuerpos contra IL-6 y usos de los mismos
PE20141162A1 (es) Anticuerpos anti-il-23
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20120415A1 (es) Anticuerpos anti-igf
AR095432A1 (es) Proteínas de unión a antígeno
EA202092735A1 (ru) Антагонизирующее cd73 антитело
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
AR103173A1 (es) Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
AR088693A1 (es) Anticuerpos especificos para trop-2 y sus usos
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
CL2012002700A1 (es) Anticuerpo humanizado capaz de logarse especificamente a receptores de quimioquina 4 (cxcr4); molecula de acido nucleico aislada que codifica dicho anticuerpo; vector y célula que comprenden dicho acido nucleico; composicion que comprende dicho anticuerpo; proceso de deteccion in vitro de la presencia y/o la ubicacion de un tumor que expresa cxcr4.
PE20181176A1 (es) Composiciones biofarmaceuticas